What is Gilotrif (afatinib) used for?
Gilotrif is the brand name of afatinib, a cancer medicine used to treat certain cases of non-small cell lung cancer (NSCLC), particularly when tumors have specific epidermal growth factor receptor (EGFR) mutations. The drug works by blocking EGFR and related signaling pathways that help cancer cells grow.
How is Gilotrif taken?
Gilotrif is taken by mouth. Dosing depends on the specific indication and tolerability. Many patients require dose adjustments if they develop side effects such as diarrhea, skin rash/acneiform dermatitis, or mouth sores.
What are common side effects people report with Gilotrif?
Commonly reported adverse effects include diarrhea, rash or acne-like skin eruptions, dry skin, mouth sores, nausea, and decreased appetite. Because these can sometimes become severe, clinicians often monitor patients closely and adjust the dose or add supportive medications.
What’s the main safety risk to know about?
Gilotrif has safety considerations typical for EGFR-targeted therapies. Serious issues can include severe skin reactions, significant diarrhea/dehydration, and rare lung inflammation (interstitial lung disease–type events). Patients are usually instructed to seek care promptly if they develop worsening breathing symptoms, severe rash, or persistent severe diarrhea.
Does a “pi” after Gilotrif mean something specific?
Your query ends with “pi,” which could mean you’re asking about one of these common follow-ups:
- “Gilotrif PI” (Package Insert prescribing information)
- “Gilotrif PI pdf” (trying to find the full label)
- “Gilotrif price” (commercial pricing)
- “Gilotrif patent info” (intellectual property status)
If you tell me which one you mean (PI, price, or patent), and your country (US/EU/etc.), I can give the most relevant, targeted answer.